Headache-related health resource utilisation in chronic and episodic migraine across six countries

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 12, 2013, Pages 1309-1317

  Sanderson, Joanna C ^a,b   Devine, Emily B ^a   Lipton, Richard B ^c   Bloudek, Lisa M ^b   Varon, Sepideh F ^b   Blumenfeld, Andrew M ^d   Goadsby, Peter J ^e   Buse, Dawn C ^c   Sullivan, Sean D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ALLERGAN INC   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d Neurology Center   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ADULT; ARTICLE; AUSTRALIA; CANADA; CAUCASIAN; CHIROPRACTOR; COMORBIDITY; CONSULTATION; DISABILITY; EMERGENCY WARD; EPISODIC MIGRAINE; ETHNIC DIFFERENCE; FEMALE; FRANCE; GERMANY; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HUMAN; INTERNIST; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; NEUROLOGIST; OBESITY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPHYLAXIS; QUESTIONNAIRE; TRANSFORMED MIGRAINE; UNITED KINGDOM; UNITED STATES;

EID: 84888020468     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-305197     Document Type: Article

References (21)

1. Olesen J, Bousser MG, Diener HC, et al.; Headache Classi fication Committee. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006;26:742-6.
2. Headache Classification Committee of The International Headache Society. The international classi fication of headache disorders (second edition). Cephalalgia 2004;24( Suppl 1):1-160.
3. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010;30:599-609.
4. Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 2012;52:1456-70.
5. Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011;31:301-15.
6. Buse D, Manack A, Serrano D, et al. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study. Headache 2012;52:3-17.
7. Stewart WF, Wood GC, Manack A, et al. Employment and work impact of chronic migraine and episodic migraine. J Occup Environ Med 2010;52:8-14.
8. Buse DC, Manack A, Serrano D, et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 2010;81:428-32.
9. Stokes M, Becker WJ, Lipton RB, et al . Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache 2011;51:1058-77.
10. Bloudek LM, Stokes M, Buse DC, et al. Cost of healthcare for patients with migraine in fi ve European countries: results from the International Burden of Migraine Study (IBMS). Headache Pain 2012;13:361-78.
11. Gerth WC, Carides GW, Dasbach EJ, et al. The multinational impact of migraine symptoms on healthcare utilisation and work loss. Pharmacoeconomics 2001;19:197-206.
12. Schoen C, Osborn R, Squires D, et al. How health insurance design affects access to care and costs, by income, in eleven countries. Health Aff (Millwood) 2010;29:2323-34.
13. Lightspeed Research. Lightspeed Online Research, Inc. c 2012 [cited 29 April 2012]. http://www.lightspeedresearch.com
14. STATA Data Analysis and Statistical Software. STATA Release 12. College Station, TX: StataCorp LP, c 1996-2012 [cited 29 April 2012]. http://www.stata.com
15. Stewart WF, Lipton RB, Dowson AJ, et al. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 2001;56(6 Suppl 1):S20-8.
16. Payne KA, Varon SF, Kawata AK, et al. The International Burden of Migraine Study (IBMS): study design, methodology, and baseline cohort characteristics. Cephalalgia 2011;31:1116-30.
17. Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007;47:355-63.
18. Berger A, Bloudek LM, Varon SF, et al. Adherence with migraine prophylaxis in clinical practice. Pain Pract 2012;12:541-9.
19. Evers S, Afra J, Frese A, et al. European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur J Neurol 2009;16:968-81.
20. Silberstein SD, Holland S, Freitag F, et al. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1337-45.
21. Bendtsen L, Evers S, Linde M, et al. EFNS. EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. Eur J Neurol 2010;17:1318-25.